摘要
目的探讨健脑素合并碳酸锂对抑郁症的疗效及安全性。方法采用随机、单盲对照法将69例抑郁症患者分为健脑素合并碳酸锂治疗组35例(研究组)和氟西汀合并碳酸锂治疗组34例(对照组)。两组疗程均为6w。于治疗前和治疗第1、2、4、6w末采用汉密顿抑郁量表评定临床疗效,副反应量表评定不良反应。结果两组治疗后各周汉密顿抑郁量表评分均较治疗前显著降低(P<0.01),治疗2w末对照组汉密顿抑郁量表减分率较研究组多(P<0.05),4、6w末无差异。疗程结束时两组显效率和有效率差异无显著性(P>0.05),副反应量表评分研究组低于对照组,差异有显著性(P<0.01)。结论健脑素联合碳酸锂治疗抑郁症与氟西汀联合碳酸锂疗效相当,但副反应少于后者。
Objective To explore the efficacy and safety of meclofenoxate hydrochloride capsules combined with lithium carbonate in the treatment of depression. Methods A random single-blind study was conducted in 69 patients with depression. The patients were assigned to research group taking meclofenoxate hydrochloride capsules combined with lithium carbonate（n=35） and control group taking fluoxetine combined with lithium carbonate（n=34） for 6 weeks. The efficacies were assessed with the Hamilton Depression Scale （HAMD）,and side effects with the Treatment Emergent Symptom Scale（TESS） before treatment and at the ends of the 1st, 2nd,4th and 6th week treatment. Results After treatment, scores of the HAMD in each week were significantly lower than those before treatment（P〈0.01） ; at the end of the 2nd week, score-reducing rate of the HAMD was more in the control than in the research group（P〈0.05） and there was no difference at the ends of 4th and 6th week. After treatment, there were no differences in effectual and effective rates between the 2 groups（P〉0.05） ; the score of the TESS were lower in the research than in the control group, difference was significant（P〈0.01）. Conclusion Efficacy of meclofenoxate hydrochloride capsules combined with lithium carbonate is equivalent to fluoxetine combined with lithium carbonate in the treatment of depression and the former has fewer side effects.
出处
《临床心身疾病杂志》
CAS
2006年第3期171-172,共2页
Journal of Clinical Psychosomatic Diseases
关键词
健脑素
碳酸锂
抑郁症
汉密顿抑郁量表
副反应量表
Meclofenoxate hydrochloride capsules
lithium carbonate
depression
the HAMD
the TESS
